MedTrace Logo

Ambrisentan for Treatment of Portopulmonary Hypertension

NCT01733095 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2016-06-17

No results posted yet for this study

Summary

Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension and is present in approximately 5% of cirrhotic patients. Treatment options include prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan.

This study investigates the safety and efficacy of ambrisentan in portopulmonary hypertension.

Conditions

  • Portopulmonary Hypertension

Interventions

DRUG

ambrisentan

Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Rudolf E. Stauber, MD · Gastroenterology & Hepatology

  • Horst Olschewski, MD · Pulmonology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-04-30
Completion
2016-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733095 on ClinicalTrials.gov